Ratings Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
5.005 USD +0.50% Intraday chart for Eiger BioPharmaceuticals, Inc. -16.02% -25.69%

Summary

  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

  • Low profitability weakens the company.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
-25.69% 7.4M
C-
+9.30% 46.03B
B
+52.73% 44.55B
A
+7.15% 40.8B
B-
-8.78% 28.25B
C
+18.68% 27.71B
B-
-21.92% 18.82B
B
+14.62% 13.91B
C+
+31.85% 12.43B
C+
+4.47% 10.81B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes